https://www.selleckchem.com/pr....oducts/tenapanor.htm
ion of preoperative radiotherapy dose is effective and oncologically safe and is associated with less morbidity than historical controls, although differences in radiotherapy techniques and follow-up should be considered. A 36-Gy dose delivered in once-daily 2-Gy fractions is proposed as a dose-fractionation approach for myxoid liposarcoma, given that phase 3 trials are logistically impossible to execute in rare cancers. ClinicalTrials.gov Identifier NCT02106312. ClinicalTrials.gov Identifier NCT02106312. One-third of singers and voca
Like
Comment
Share
